[{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Prestige Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Sodium Carboxymethylcellulose","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Akorn Pharmaceuticals \/ Prestige Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Prestige Consumer Healthcare"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Akorn Pharmaceuticals \/ Th\u00e9a","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Th\u00e9a"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Th\u00e9a Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Akorn Pharmaceuticals \/ Th\u00e9a Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Th\u00e9a Pharma"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Akorn Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Cetrorelix Acetate is used to prevent premature ovulation during controlled ovarian stimulation. Cetrorelix blocks the effects of a natural hormone, called GnRH. GnRH controls the secretion of another hormone, called LH, which induces ovulation during th...

                          Brand Name : Cetrorelix Acetate-Generic

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 27, 2022

                          Lead Product(s) : Cetrorelix Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Cetrorelix Acetate for Injection 0.25 mg is used to prevent premature ovulation during controlled ovarian stimulation, for Injection blocks such undesirable premature ovulation.

                          Brand Name : Cetrorelix Acetate-Generic

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 16, 2022

                          Lead Product(s) : Cetrorelix Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under the deal, Théa Pharma acquired seven products including established glaucoma therapies Zioptan®, Cosopt®, Cosopt® PF, and Betimol®, along with Azasite®, Akten®, and the ocular surface repair agent AcellFX™.

                          Brand Name : Zioptan

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 09, 2022

                          Lead Product(s) : Tafluprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Théa Pharma

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The purchase will add seven established brands, including Akorn’s leading glaucoma therapy, Zioptan®, to Théa’s portfolio. Théa will also welcome Akorn’s nearly 50-person sales force, which Théa expects to expand in support of anticipated growt...

                          Brand Name : Zioptan

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 28, 2022

                          Lead Product(s) : Tafluprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Laboratoires Thea

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The Consumer Health business primarily consists of the following over-the-counter brands: TheraTears , Diabetic Tussin , MagOx , Multi-betic , and Zostrix.

                          Brand Name : TheraTears

                          Molecule Type : Small molecule

                          Upfront Cash : $230.0 million

                          May 27, 2021

                          Lead Product(s) : Sodium Carboxymethylcellulose

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Prestige Consumer Healthcare

                          Deal Size : $230.0 million

                          Deal Type : Divestment

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Loteprednol Etabonate Ophthalmic Gel, 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 11, 2021

                          Lead Product(s) : Loteprednol Etabonate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank